Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210793 | 0.86 | ALDH1A1 (0.35) | FFAR3ALDH1A1 | |
| SCHEMBL3375229 | 0.81 | CYP4F2 (0.33) | FFAR3CYP4A11CYP4F2ADORA2AADORA1 | |
| SCHEMBL20162490 | 0.81 | CYP4F2 (0.33) | FFAR3CYP4A11CYP4F2ADORA2AADORA1 | |
| SCHEMBL10210767 | 0.78 | PKM (0.39) | — | |
| SCHEMBL10336598 | 0.78 | CCR2 (0.39) | CYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL893183 | 0.78 | FFAR3 (0.44) | FFAR3 | |
| SCHEMBL18202993 | 0.77 | GRM1 (0.38) | FFAR3ALDH1A1 | |
| SCHEMBL20944070 | 0.77 | FFAR3 (0.32) | FFAR3CYP4A11CYP4F2 | |
| SCHEMBL836834 | 0.76 | CCR2 (0.44) | CYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL1393075 | 0.75 | USP2 (0.35) | FFAR3CYP4A11CYP4F2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1581515-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-5182047-A | FLUORINATED BIPHENYLDIOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1993-01-26 | — | — | US | disclosed |
| EP-0368975-A1 | FLUORINATED BIPHENYLDIOLE DERIVATIVES. | MERCK PATENT GMBH (DE) | 1990-05-23 | — | — | EP | disclosed |
| WO-1989012039-A1 | FLUORINATED BIPHENYLDIOLE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | FFAR3 3437/4885CYP4A11 1793/4885CYP4F2 2810/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | FFAR3 3610/4885CYP4A11 1781/4885CYP4F2 2696/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | FFAR3 3437/4885CYP4A11 1793/4885CYP4F2 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.